Please login to the form below

Not currently logged in
Email:
Password:

Krystexxa

This page shows the latest Krystexxa news and features for those working in and with pharma, biotech and healthcare.

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

biotech company where we will build on the success of Tepezza and Krystexxa to bolster our long-term growth trajectory,” he added.

Latest news

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    575. Crealta. Horizon. Acquisition - company. Krystexxa marketed for treatment of chronic refractory gout.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics